Prathibha Mohan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Prathibha Mohan has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Viraj R. Sanghvi
Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA
25 shared publications - Zhengqing Ouyang
Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, USA
24 shared publications Agnes Viale
23 shared publicationsAntonija Burčul
23 shared publicationsMan Jiang
23 shared publicationsAskan Gokce
22 shared publications
Latest Publications
- Open Access
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Targeting eIF4A-dependent translation in genetically complex sarcoma
Dedifferentiated liposarcoma (DDLS), myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma (UPS) are the most common types of genetically complex sarcoma. There is an urgent need to develop effective targeted therapy for these deadly sarcoma types. Despite their genetic complexity, these sarcomas share genomic alterations causing PI3K/Akt/mTOR and MAPK pathway activation, and both pathways control translation mediated by the RNA helicase eIF4A. We therefore investigated eIF4A inhibition as a therapeutic strategy. The eIF4A inhibitor CR-1-31B effectively suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS patient–derived cell lines and mouse xenografts. Transcriptome-scale ribosome footprinting identified eIF4A-dependent mRNAs such as the Hippo pathway transcriptional coactivators YAP1 (YAP) and WWTR1 (TAZ). Combined knockdown of YAP and TAZ induced apoptosis in DDLS, MFS, and UPS cell lines, and their ectopic expression partially rescued cells from apoptosis induced by CR-1-31B. Genomic analysis of patient tumors revealed that YAP and WWTR1 were frequently amplified or gained in DDLS, MFS, and UPS and were associated with worse clinical outcomes. Together, our findings identify a strategy for targeting the Hippo pathway in incurable forms of sarcoma based on inhibition of eIF4A-dependent translation of the key oncogenic transcription factors YAP and TAZ.
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Open AccessTargeting eIF4A-dependent translation in genetically complex sarcoma
Dedifferentiated liposarcoma (DDLS), myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma (UPS) are the most common types of genetically complex sarcoma. There is an urgent need to develop effective targeted therapy for these deadly sarcoma types. Despite their genetic complexity, these sarcomas share genomic alterations causing PI3K/Akt/mTOR and MAPK pathway activation, and both pathways control translation mediated by the RNA helicase eIF4A. We therefore investigated eIF4A inhibition as a therapeutic strategy. The eIF4A inhibitor CR-1-31B effectively suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS patient–derived cell lines and mouse xenografts. Transcriptome-scale ribosome footprinting identified eIF4A-dependent mRNAs such as the Hippo pathway transcriptional coactivators YAP1 (YAP) and WWTR1 (TAZ). Combined knockdown of YAP and TAZ induced apoptosis in DDLS, MFS, and UPS cell lines, and their ectopic expression partially rescued cells from apoptosis induced by CR-1-31B. Genomic analysis of patient tumors revealed that YAP and WWTR1 were frequently amplified or gained in DDLS, MFS, and UPS and were associated with worse clinical outcomes. Together, our findings identify a strategy for targeting the Hippo pathway in incurable forms of sarcoma based on inhibition of eIF4A-dependent translation of the key oncogenic transcription factors YAP and TAZ.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Pancreatic adenocarcinoma (PDAC) epitomizes a deadly cancer driven by abnormal KRAS signaling. Here, we show that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and that pharmacological inhibition of eIF4A has single-agent activity against murine and human PDAC models at safe dose levels. EIF4A was uniquely required for the translation of mRNAs with long and highly structured 5′ untranslated regions, including those with multiple G-quadruplex elements. Computational analyses identified these features in mRNAs encoding KRAS and key downstream molecules. Transcriptome-scale ribosome footprinting accurately identified eIF4A-dependent mRNAs in PDAC, including critical KRAS signaling molecules such as PI3K, RALA, RAC2, MET, MYC, and YAP1. These findings contrast with a recent study that relied on an older method, polysome fractionation, and implicated redox-related genes as eIF4A clients. Together, our findings highlight the power of ribosome footprinting in conjunction with deep RNA sequencing in accurately decoding translational control mechanisms and define the therapeutic mechanism of eIF4A inhibitors in PDAC.Significance:These findings document the coordinate, eIF4A-dependent translation of RAS-related oncogenic signaling molecules and demonstrate therapeutic efficacy of eIF4A blockade in pancreatic adenocarcinoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Pancreatic adenocarcinoma (PDAC) epitomizes a deadly cancer driven by abnormal KRAS signaling. Here, we show that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and that pharmacological inhibition of eIF4A has single-agent activity against murine and human PDAC models at safe dose levels. EIF4A was uniquely required for the translation of mRNAs with long and highly structured 5′ untranslated regions, including those with multiple G-quadruplex elements. Computational analyses identified these features in mRNAs encoding KRAS and key downstream molecules. Transcriptome-scale ribosome footprinting accurately identified eIF4A-dependent mRNAs in PDAC, including critical KRAS signaling molecules such as PI3K, RALA, RAC2, MET, MYC, and YAP1. These findings contrast with a recent study that relied on an older method, polysome fractionation, and implicated redox-related genes as eIF4A clients. Together, our findings highlight the power of ribosome footprinting in conjunction with deep RNA sequencing in accurately decoding translational control mechanisms and define the therapeutic mechanism of eIF4A inhibitors in PDAC.Significance:These findings document the coordinate, eIF4A-dependent translation of RAS-related oncogenic signaling molecules and demonstrate therapeutic efficacy of eIF4A blockade in pancreatic adenocarcinoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules